🟠 Moderate Evidence
Most people taking vitamin C supplements consume 1,000mg in a single dose, yet widespread criticism suggests that such doses are wasteful because intestinal absorption becomes inefficient above 200mg. This consensus, however, rests on a misreading of the underlying pharmacokinetic data. Research published in the Proceedings of the National Academy of Sciences (PNAS) in 1996 by Mark Levine and colleagues demonstrates that while the fraction of vitamin C absorbed declines steeply above 200mg, the absolute amount absorbed continues to rise—a distinction that fundamentally changes how we should interpret supplement efficacy.
Key takeaways
- Bioavailability of vitamin C is 100% at 200mg but drops to 50% at 1,000mg—yet absolute absorption (not percentage) continues to increase at higher doses
- Recent pharmacokinetic studies show that at 1,000mg, a person absorbs approximately 500mg of actual vitamin C, compared to 200mg at the 200mg dose
- Immune cells (neutrophils, monocytes, lymphocytes) actively concentrate vitamin C intracellularly to 50–100 times plasma concentration, suggesting that higher serum levels may have functional relevance despite lower bioavailability percentages
Study at a Glance
| Source | Proceedings of the National Academy of Sciences (PNAS) |
| Study type | Controlled pharmacokinetic trial |
| Sample size | N = 7 healthy men (1996); N = 15 women (2001 confirmatory study) |
| Population | Healthy adults; baseline diet contained <5mg vitamin C per day |
| Country | United States |
Vitamin C Absorption: Declining Bioavailability, Rising Absolute Intake
Percentage bioavailability vs. absolute milligrams absorbed across sequential doses (Levine et al., 1996)
Source: Levine et al., PNAS, 1996 | Georgian Medical Journal News
The Saturation Curve: Why Bioavailability Declines Above 200mg
The landmark 1996 study by Levine and colleagues, published in PNAS, enrolled seven healthy men who were hospitalized for 4 to 6 months and maintained on a severely restricted diet containing less than 5mg of vitamin C per day. Once depleted, participants were sequentially repleted at doses ranging from 30mg to 2,500mg, with steady-state plasma concentrations measured at each level.
The absorption curve follows a sigmoidal pattern, driven by saturation of the sodium-dependent vitamin C transporter SVCT1 in the intestine. At 200mg, bioavailability is complete (100%)—every milligram absorbed reaches systemic circulation. But as dose increases, two mechanisms reduce the fraction absorbed: the transporter becomes saturated, and renal excretion of unabsorbed vitamin C increases. A 2001 confirmatory study by the same group, also in PNAS, replicated this pattern in 15 women, confirming that the pharmacokinetic ceiling is independent of sex.
At 1,000mg, bioavailability drops to roughly 50%, yet the absolute amount absorbed—approximately 500mg—is 2.5 times higher than the 200mg absorbed from a 200mg dose.
— Mark Levine, Chief of the Molecular and Clinical Nutrition Section, National Institutes of Health (PNAS, 1996)
Absolute Absorption Versus Bioavailability Percentage: The Overlooked Distinction
Most criticism of high-dose vitamin C supplementation stops at bioavailability percentage, concluding that doses above 200–500mg are wasteful. This interpretation conflates two separate measures. Bioavailability percentage describes the fraction of an administered dose that enters the bloodstream; absolute absorption describes the actual number of milligrams absorbed.
The data from Levine’s 1996 PNAS study show that at every dose increase above 200mg, the total milligrams absorbed rises even as the efficiency (percentage) falls. At 500mg, a person absorbs approximately 365mg (73% of the dose). At 1,000mg, approximately 500mg is absorbed (50% of the dose). At 1,250mg, approximately 410mg is absorbed (33% of the dose). Less efficient per milligram does not mean useless; it means a higher dose is required to achieve proportionally greater systemic delivery.
This distinction has particular importance because plasma vitamin C concentration does not tell the complete story. Immune cells—including neutrophils, monocytes, and lymphocytes—possess a second vitamin C transporter, SVCT2, which actively concentrates the micronutrient to intracellular levels 50 to 100 times higher than plasma concentration. In healthy individuals consuming at least 100mg per day, intracellular vitamin C concentrations reach approximately 1.5 mM in neutrophils and 3.5 mM in lymphocytes. These cells saturate only at much higher supply levels than commonly assumed, suggesting that higher oral doses may have functional immunological relevance despite modest bioavailability percentages.
Clinical and Practical Implications: Efficacy Is Not Determined by Absorption Alone
The pharmacokinetic data compiled by Levine and colleagues in PNAS (1996) and confirmed in their 2001 follow-up study challenge a widespread oversimplification in public health messaging. The statement that “you only absorb 200mg at a time” conflates the dose at which saturation begins with the dose at which absorption stops increasing. These are not equivalent. A dose of 1,000mg delivers five times as much vitamin C to the bloodstream as 200mg, even though the percentage absorbed is lower.
Whether such high-dose supplementation confers clinical benefit remains an active area of investigation and falls outside the scope of these pharmacokinetic studies. However, understanding the true absorption curve—both bioavailability percentage and absolute intake—is essential for informed decision-making by consumers, clinicians, and researchers designing vitamin C trials. The evidence suggests that dismissing 1,000mg supplements as entirely wasteful misrepresents the underlying biology.
What this means
Frequently asked questions
If bioavailability at 1,000mg is only 50%, am I really absorbing 500mg?
Yes. According to Levine et al. (PNAS, 1996), at a 1,000mg dose, approximately 500mg enters the bloodstream. Bioavailability percentage (50%) describes the fraction of the dose absorbed; absolute absorption (500mg) describes the actual milligrams delivered to systemic circulation. The latter is what determines plasma and intracellular vitamin C concentrations.
Can my body use 500mg of vitamin C from a 1,000mg supplement, or is it excess?
Your body can use at least 500mg acutely; the question is whether it benefits clinically. Levine’s research (PNAS, 1996) shows that immune cells concentrate vitamin C intracellularly to levels 50–100 times higher than plasma, and these cells only saturate at very high supply levels. Whether 500mg per dose produces measurable health benefits in healthy individuals versus 200mg remains an open clinical question, not resolved by pharmacokinetics alone.
Does the 200mg absorption ceiling mean I should never take more than 200mg at once?
No. The 200mg dose achieves 100% bioavailability, but 1,000mg and 1,250mg doses still deliver 500mg and 410mg, respectively, to your bloodstream—far more than 200mg. The “ceiling” refers to the dose at which saturation becomes significant, not the dose at which absorption stops increasing. Levine et al. (PNAS, 1996) found that even at 2,500mg, meaningful absorption occurs, albeit with sharply declining percentage efficiency.
As vitamin C supplementation continues to be widely adopted globally, more rigorous clinical trials comparing different dosing strategies in specific populations—such as individuals with chronic illness, intensive exercise demands, or metabolic stress—would help clarify whether the additional absolute absorption achieved at higher doses translates into meaningful clinical benefit. Until then, consumers and health professionals should rely on accurate pharmacokinetic data rather than oversimplified absorption myths to guide supplementation decisions.
Source: Levine et al. vitamin C pharmacokinetic studies (PNAS, 1996 and 2001)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
